Evidence map›Paper›PMID 34697062›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2022

Circulating Inflammation Markers and Pancreatic Cancer Risk: A Prospective Case-Cohort Study in Japan.

Enbo Ma, Taichi Shimazu, Minkyo Song, Hadrien Charvat, Norie Sawada, Taiki Yamaji, Manami Inoue, M Constanza Camargo, Troy J Kemp, Ruth M Pfeiffer and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Enbo Ma *Health Promotion Center, Fukushima Global Medical Science Center, Fukushima Medical University, Fukushima, Japan.ORCID 0000-0001-6320-9360
Taichi Shimazu *Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan. tshimazu@ncc.go.jp.ORCID 0000-0001-6000-9830
Minkyo SongDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-9412-2871
Hadrien CharvatEpidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Norie SawadaEpidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.ORCID 0000-0002-9936-1476
Taiki YamajiEpidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Manami InoueEpidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.ORCID 0000-0003-1276-2398
M Constanza CamargoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Troy J KempHPV Immunology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Ruth M PfeifferDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0001-7791-2698
Ligia A PintoHPV Immunology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Charles S RabkinDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Shoichiro TsuganeEpidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Prevention Group · USNational Cancer Institute · USLeidos (United States) · USFukushima Medical University · JP

Funding

Molecular mechanisms of infection-related cancerZIACP010212 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ENGELS, ERIC A · 2010 to 2025
$4.6M
Intramural NIH HHS ZIA CP010212
6 · The paper itself

Abstract

backgroundPrevious prospective studies of associations between circulating inflammation-related molecules and pancreatic cancer risk have included limited numbers of markers.

methodsWe conducted a case-cohort study nested within the Japan Public Health Center-based Prospective Study Cohort II. We selected a random subcohort (

resultsThe HR (95% CI) for the highest versus the lowest category of C-C motif ligand chemokine 8/monocyte chemoattractant protein 2 (CCL8/MCP2) was 2.03 (1.05-3.93;

conclusionsWe found no significant associations between 62 inflammatory markers and pancreatic cancer risk. IMPACT: The suggestive association with circulating levels of leukocyte recruiting cytokine CCL8/MCP2 may warrant further investigation.

Indexed as

AdultAgedBiomarkers, TumorChemokinesCytokinesFemaleHumansInflammationIntercellular Signaling Peptides and ProteinsJapanMaleMiddle AgedPancreatic NeoplasmsProspective StudiesSurveys and QuestionnairesBiomarkers, TumorChemokinesCytokinesIntercellular Signaling Peptides and Proteins

Identifiers

PMID34697062
PMCPMC8755613
OpenAlexW3210757268

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.